Melanoma Vaccines (Imlygic/talimogene laherparepvec)
Customize your policy alerts
Sign up for Anthem Policy CC-0135 alerts
Get alerted when Policy CC-0135 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for use of Imlygic (talimogene laherparepvec) and other melanoma vaccines under the medical benefit for members; applies to coverage decisions for melanoma and select Merkel cell carcinoma indications.
Updated per NCCN 2A for Merkel cell carcinoma intralesional treatment for primary N+ M0 disease or recurrent N+ regional disease if curative surgery and curative RT are not feasible.
Wording and formatting criteria updates; criteria aligned with NCCN 2A language and inclusion of oligometastatic and widely disseminated disease per NCCN.
Removed HCPCS NOC J3590 from coding list.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.